Skip to search formSkip to main contentSkip to account menu

Celgene

An American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Phase 2 AFFINITY trial evaluates opicinumab in a targeted population of patients with relapsing multiple sclerosis: rationale, design and baseline characteristics
Relapsing Multiple Sclerosis: Rationale, Design and Baseline Characteristics Bing Zhu, Peter Calabresi, Gavin Giovannoni, Raju… 
2017
2017
Results from the Hgb-207 (Northstar-2) Trial: A Phase 3 Study to Evaluate Safety and Efficacy of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in Patients with Non-β0/β0…
Background Gene therapy with LentiGlobin Drug Product (DP), which contains autologous CD34+ hematopoietic stem cells transduced… 
2015
2015
Infliximab drug and antibody levels in patients with dermatological conditions
Background In recent years, studies monitoring infliximab in rheumatoid arthritis and inflammatory bowel disease have confirmed… 
2015
2015
ADVANCES IN ACUTE MYELOID LEUKEMIA An update of current treatments for adult acute myeloid leukemia
Recentadvances inacutemyeloid leukemia (AML) biology and its genetic landscape should ultimately lead to more subsetspecific AML… 
Review
2012
Review
2012
Lack of Response of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) to Decitabine After Failure of Azacitidine
Abstract 3858 Background: Standard therapy for high-risk MDS consists of one of two FDA-approved demethylating agents… 
2012
2012
Texas legitimizes path around FDA oversight
2010
2010
Targeting tumour metabolism
2010
2010
Deal watch: Celgene acquires Gloucester Pharmaceuticals, gaining approved HDAC inhibitor
2009
2009
Whole Genome Paired End Sequencing Identifies Genomic Evolution in Myeloma.
Abstract 2846 Poster Board II-822 Background: A prominent feature of most cancers is striking genetic instability and ongoing… 
2008
2008
A phase I, open-label, dose-escalation study to evaluate the safety, pharmacokinetics, and pharmacodynamics of oral azacitidine in subjects with myelodysplastic syndromes (MDS) or acute myelogenous…
7091 Background: Azacitidine, a cytidine analog, through its effects on DNA metabolism, gene expression, and cell differentiation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)